
    
      A total of 98 patients with HER2 positive AGC were enrolled in this prospective observational
      study. All patients were treated with trastuzumab plus chemotherapy as the first line
      therapy. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data
      were collected to evaluate the potential prognostic factors on progressive free survival.
    
  